Search

Search

Log in or registerMenuClose

Search

Rankings
Firms & Lawyers
In-House
- In-House Content
- GC Powerlist
Knowledge Centre
- About us

Comparative Guides
Events
Legal 500 TV

About us

Legal 500
FAQs
Marketing
Careers
Trust Centre
Contact us

Deutschland DE
Paris FR

Rankings
Firms & Lawyers
In-House
- In-House Content
- GC Powerlist
Knowledge Centre
- About us

Comparative Guides
Events
Legal 500 TV

About us

Legal 500
FAQs
Marketing
Careers
Trust Centre
Contact us

Deutschland DE
Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

Legal 500 Trust Centre
Contact Us

Market Intelligence
Search

Your search for ‘Pomerantz LLP’ returned 6 results

Use advanced search filters to refine your search

Search

Advanced search filters

Topics

Search for topics

Countries

Search for countries

Contributor

Search to show contributors

Start typing to add contributors

Content type

Any
Article
Podcast
Video

Sort by

Article
Regulation A+ Earns A D
For more than eight decades, the Securities Act of 1933 has protected investors by requiring full disclosure in initial public offerings. As President Roosevelt explained at the time of its enactment ...
United StatesCorporate/Commercial Law
Pomerantz LLP
Article
Dechert Survey: Developments In Securities Fraud Class Actions Against U.S. Life Sciences Companies
2017 was a record year for class action securities litigation, and life sciences companies continued to be popular targets of such lawsuits.
GermanyCorporate/Commercial Law
Dechert LLP

Article

Developments In Securities Fraud Class Actions Against U.S. Life Sciences Companies

Last year marked an increase in federal securities class action filings, with plaintiffs filing 213 cases in 2023, up from 197 in 2022 and ending an overall decline in filings since 2019.

United StatesLitigation, Mediation & Arbitration

Dechert

Developments In Securities Fraud Class Actions Against U.S. Life Sciences Companies

Last year marked a decrease in federal securities class action filings, with plaintiffs filing 207 cases in 2025, down from 225 in 2024. However, life sciences companies remained popular targets, accounting for 47 of these filings.1 In this White Paper, we examine 2025's filing and decision trends and provide insights to help life sciences companies navigate the litigation landscape prudently.

United StatesCorporate/Commercial Law

COVID-19: An Early Look At Securities Act Litigation Amid COVID-19

As noted in our earlier alert concerning securities fraud litigation under Section 10(b) of the Securities Exchange Act, the spread of COVID-19 and its effect on the global economy have caused

United StatesCoronavirus (COVID-19)

U.S. Securities Fraud Class Actions Against Non-U.S. Issuers: 2024 Developments

In 2024, plaintiffs filed 36 securities class action lawsuits against non-U.S. issuers, up by three from the 33 filings in 2023.

GlobalCorporate/Commercial Law

Showing 1–6 of 6 results

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics